Organon & Company Supports May Health's Leadership Change in Pioneering PCOS Treatment
- May Health appoints Colby Holtshouse as President and CEO to lead innovative PCOS treatment development.
- The REBALANCE study aims to secure marketing authorization for the Ovarian Rebalancing procedure, enhancing women's health options.
- May Health is committed to advancing reproductive health technologies, addressing urgent needs for effective PCOS treatments.
May Health Appoints New Leadership Amidst Pioneering PCOS Treatment Development
May Health, a clinical-stage medical device company, is making headlines with its innovative approach to treating Polycystic Ovary Syndrome (PCOS), a leading cause of infertility that affects around 10% of women globally. Recently, the company announces the appointment of Colby Holtshouse as President and CEO, a strategic move that aligns with the ongoing clinical evaluation of its Ovarian Rebalancing™ technology. This groundbreaking procedure aims to provide a solution for women who do not respond to traditional oral medications, a critical advancement in the women's health sector.
With an extensive background in women's health, Holtshouse's leadership is seen as pivotal during the REBALANCE study, which is an investigational device exemption (IDE) clinical trial intended to secure marketing authorization for the Ovarian Rebalancing procedure. The technique itself is a one-time, ultrasound-guided transvaginal ablation that utilizes radio frequency energy to ablate excess androgen-producing ovarian tissue. This innovative approach not only seeks to restore ovulation but is designed for same-day recovery, minimizing disruption to patients’ lives. Dr. Robert Auerbach, Chairman of May Health, expresses optimism about Holtshouse's guidance as the company progresses towards commercialization, potentially transforming the lives of millions of women battling PCOS-related infertility.
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, emphasizes the significance of May Health’s pioneering strategy in addressing PCOS infertility. The excitement surrounding Holtshouse’s appointment reflects a broader recognition of the urgent need for effective treatments in women's health. As May Health moves forward, it stands at a crucial juncture that could redefine the therapeutic landscape for PCOS, offering hope and new solutions to women around the world.
In other developments, May Health's REBALANCE study underscores the company's commitment to advancing women's health technologies. The trial not only aims to validate the Ovarian Rebalancing procedure but also positions May Health as a leader in the clinical evaluation of medical devices for reproductive health. This focus underlines the importance of innovative solutions in addressing conditions that have long been overlooked in the medical community.
As the company prepares for commercialization, the leadership transition to Holtshouse comes at a time when the demand for effective PCOS treatments is rising. With a strong emphasis on research and development, May Health is poised to make significant contributions to the field, potentially improving the quality of life for countless women worldwide.